Core Insights - Fosun Pharma's subsidiary, Fosun Wanbang, launched the topical anesthetic, Rize Lin® (Lidocaine/Prilocaine Cream), on Alibaba Health, marking a strategic expansion into the outpatient market [1] - The product has a long-standing global application history and is approved for pain relief in skin punctures and superficial surgical procedures in China since 1998 [1] - The growth of the aesthetic and men's health sectors has led to increased visibility and application of the product in outpatient settings, with it being recommended as a first-line option in guidelines for premature ejaculation [1] Market Performance - The Rize Lin® cream has shown steady growth in both public hospitals and consumer medical markets, with projected sales in public medical institutions exceeding 420 million yuan in 2024 [1] - The total market size for Rize Lin® cream, including applications in aesthetic medicine and premature ejaculation, is expected to surpass 1 billion yuan [1] Regulatory and Academic Support - In 2024, the National Medical Products Administration released technical guidelines for the bioequivalence study of Lidocaine/Prilocaine cream, and the first clinical application consensus for skin surface anesthetics was published [2] - International guidelines from organizations like the European Urological Association have also recommended such compounded creams, providing a robust regulatory and academic framework for Rize Lin® [2] Strategic Collaboration - The partnership with Alibaba Health leverages its platform advantages in digital health services, aiming to reach consumers who prioritize privacy, convenience, and safety [2]

Group 1: Company Strategy and Market Focus - In 2026, the company will focus on stabilizing its existing business and driving innovation through a dual approach, emphasizing both hospital and external markets [2][3] - Key products in the external market include Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, and other newly acquired exclusive varieties [4] - The company aims to enhance brand recognition and terminal coverage through the new "JiuDian Pain Relief" brand image [2] Group 2: Innovation and Product Development - The company will continue to adopt a strategy of "independent research and project introduction" for innovative drugs, actively seeking competitive projects [5] - Plans to enrich the product pipeline through collaborative research and development, as well as industry-academia transformation [5] Group 3: Financial Outlook and Shareholder Returns - The company will develop a scientific and sustainable shareholder return plan over the next 2-3 years based on operational performance and market conditions [8] - There is a potential for further acquisitions to enhance the product line and business layout as needed [8] Group 4: Market Challenges and Pricing Impact - The implementation of centralized procurement for Loxoprofen Sodium Gel Patch may lead to a temporary decrease in gross margin due to price adjustments [7] - The company will maintain a stable overseas business primarily focused on the export of raw materials and pharmaceutical excipients [6]